Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.49 |
| ▸ | CTSB | P07858 | 10/20 | 0.49 |
| ▸ | CTSD | P07339 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5647762 | 1.00 | BACE1 (0.49) | BACE1CTSBCTSDCYP3A4 | |
| SCHEMBL14348121 | 0.95 | BACE1 (0.55) | BACE1CTSBCTSD | |
| SCHEMBL4666424 | 0.92 | BACE1 (0.58) | BACE1CTSBCTSD | |
| SCHEMBL4666419 | 0.92 | BACE1 (0.58) | BACE1CTSBCTSD | |
| SCHEMBL4666291 | 0.90 | BACE1 (0.51) | BACE1CTSBCTSDCYP3A4 | |
| SCHEMBL4666285 | 0.90 | BACE1 (0.51) | BACE1CTSBCTSDCYP3A4 | |
| SCHEMBL4666358 | 0.87 | CTSB (0.63) | BACE1CTSB | |
| SCHEMBL4666372 | 0.87 | CTSB (0.63) | BACE1CTSB | |
| SCHEMBL14348120 | 0.87 | BACE1 (0.65) | BACE1CTSBCTSD | |
| SCHEMBL14348124 | 0.85 | BACE1 (0.56) | BACE1CTSBCTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395551-B1 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | ELAN PHARM INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166717-A1 | Hydroxy alkyl amines | PSEN1, MAOA, PSEN2 | BACE1 47/4885CTSB 2908/4885CTSD 3148/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | BACE1 67/4885CTSB 2593/4885CTSD 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.